Ranolazine Mechanism and Clinical Considerations

Mechanism of Action and Hemodynamic Effects

Ranolazine works primarily through inhibition of the late sodium current (late INa), which prevents intracellular calcium overload during ischemia, according to the American College of Cardiology guidelines 1
Ranolazine has a neutral hemodynamic profile, exerting its antianginal effects without significantly affecting heart rate or blood pressure, making it potentially useful in cases of bradycardia and/or hypotension where other antianginal agents might worsen these conditions, as recommended by the European Society of Cardiology 2

Ranolazine is contraindicated in patients with hepatic impairment or liver cirrhosis, and should be used with caution in patients taking digoxin, as stated by the American Heart Association 2
The American Diabetes Association notes that patients with diabetes and chronic stable angina might benefit from ranolazine treatment, as it has been shown to reduce glycated hemoglobin levels 2

Patients with left ventricular hypertrophy might experience greater efficacy with ranolazine compared to other antianginal drugs, according to the European Society of Cardiology 2

When prescribing ranolazine, healthcare providers should be aware that it may interact with other medications that can affect blood pressure, and should monitor patients for symptoms of hypotension, particularly when initiating therapy or increasing the dose, as recommended by the American College of Cardiology 3